CFAH VHIO – Vall d'Hebron Institute of Oncology

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

VHIO is taking part in the development of a latest-generation antibody that will offer an alternative for immunotherapy-resistant tumours

13/05/2022|Comments Off on VHIO is taking part in the development of a latest-generation antibody that will offer an alternative for immunotherapy-resistant tumours

VHIO’s Scientific Report 2021: Turning 15 and driving continued, ‘crystalized’ progress against cancer during COVID-19 pandemic waves

09/05/2022|Comments Off on VHIO’s Scientific Report 2021: Turning 15 and driving continued, ‘crystalized’ progress against cancer during COVID-19 pandemic waves

Precision medicine can help to improve existing therapies for patients with metastatic colorectal cancer

03/05/2022|Comments Off on Precision medicine can help to improve existing therapies for patients with metastatic colorectal cancer

Elena Garralda’s latest ESMO On target column: Age is ‘just a number’. Not so in clinical trial enrollment

26/04/2022|Comments Off on Elena Garralda’s latest ESMO On target column: Age is ‘just a number’. Not so in clinical trial enrollment

VHIO is involved in the development of a new antibody targeting cancer stem cells of solid tumours

25/04/2022|Comments Off on VHIO is involved in the development of a new antibody targeting cancer stem cells of solid tumours

  • Dr. Elena Garralda

Precision medicine still has hurdles to overcome to reach all patients

19/04/2022|Comments Off on Precision medicine still has hurdles to overcome to reach all patients

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2021

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – CAIXARESEARCH
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS